Structure Therapeutics (GPCR) Competitors $30.06 -0.13 (-0.41%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. CRSP, NUVL, AXSM, LEGN, TGTX, PCVX, MTSR, KRYS, PTCT, and ARWRShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), TG Therapeutics (TGTX), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors CRISPR Therapeutics Nuvalent Axsome Therapeutics Legend Biotech TG Therapeutics Vaxcyte Metsera Krystal Biotech PTC Therapeutics Arrowhead Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends. Is GPCR or CRSP more profitable? Structure Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Which has more risk & volatility, GPCR or CRSP? Structure Therapeutics has a beta of -1.65, indicating that its share price is 265% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Do institutionals and insiders believe in GPCR or CRSP? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, GPCR or CRSP? Structure Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-28.61CRISPR Therapeutics$37.31M171.36-$366.25M-$5.43-12.95 Do analysts prefer GPCR or CRSP? Structure Therapeutics presently has a consensus price target of $68.67, indicating a potential upside of 128.58%. CRISPR Therapeutics has a consensus price target of $71.71, indicating a potential upside of 2.01%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89CRISPR Therapeutics 2 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.42 Does the media prefer GPCR or CRSP? In the previous week, CRISPR Therapeutics had 9 more articles in the media than Structure Therapeutics. MarketBeat recorded 16 mentions for CRISPR Therapeutics and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.91 beat CRISPR Therapeutics' score of 0.74 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStructure Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73B$3.37B$6.05B$10.51BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-28.6522.2185.5327.36Price / SalesN/A472.84592.56135.63Price / CashN/A44.9825.7730.18Price / Book1.9910.4612.696.79Net Income-$122.53M-$52.58M$3.32B$276.59M7 Day Performance5.70%1.15%0.58%1.08%1 Month Performance43.66%14.95%9.50%8.50%1 Year Performance-17.97%21.65%79.27%44.54% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics3.1722 of 5 stars$30.07-0.4%$68.67+128.4%-21.2%$1.73BN/A-28.67136CRSPCRISPR Therapeutics1.6567 of 5 stars$70.19+3.6%$71.50+1.9%+45.8%$6.16B$35M-12.93460Analyst ForecastNUVLNuvalent2.7703 of 5 stars$83.85-0.4%$118.89+41.8%-13.4%$6.07BN/A-17.1140AXSMAxsome Therapeutics4.6972 of 5 stars$119.94-0.3%$177.93+48.4%+38.4%$6.00B$495.03M-23.66380Analyst RevisionLEGNLegend Biotech2.5988 of 5 stars$31.44-1.9%$74.22+136.1%-34.3%$5.92B$627.24M-35.732,609Gap DownTGTXTG Therapeutics4.4629 of 5 stars$36.76+0.1%$49.00+33.3%+54.3%$5.82B$454.07M99.35290PCVXVaxcyte2.4731 of 5 stars$41.21-3.4%$106.25+157.8%-61.7%$5.54BN/A-10.03160Analyst ForecastMTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.45BN/A0.0081KRYSKrystal Biotech4.4448 of 5 stars$180.57-1.5%$209.00+15.7%+3.4%$5.31B$359.21M36.70210Analyst RevisionPTCTPTC Therapeutics3.2925 of 5 stars$64.80-0.9%$69.00+6.5%+69.4%$5.19B$1.76B9.301,410Analyst RevisionARWRArrowhead Pharmaceuticals4.0727 of 5 stars$37.50+3.8%$43.14+15.0%+96.6%$4.99B$3.55M-29.30400 Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Vaxcyte Alternatives Metsera Alternatives Krystal Biotech Alternatives PTC Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
